Biogen

News

Closeup of X-ray photography of human brain

Biogen, Eisai hit hard as Alzheimer’s drug is abandoned

The dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, after Biogen and Eisai pulled the plug on aducanumab.

News

Biogen buys UK gene therapy firm Nightstar for $800m

Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million.

Views & Analysis

R&D roundup – Sage impresses at JP Morgan

One of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling promising data from an up-rated phase III trial of its postpartum

News

Pair of deals boosts Biogen’s early-stage CNS pipeline

Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.

News

Roche's SMA drug gets PRIME regulatory status in Europe

Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it speci

News

Alkermes/Biogen hope for less tummy trouble with new MS pill

Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s o

Biogen, Eisai hit hard as Alzheimer’s drug is abandoned

Biogen buys UK gene therapy firm Nightstar for $800m

R&D roundup – Sage impresses at JP Morgan

Pair of deals boosts Biogen’s early-stage CNS pipeline

Roche's SMA drug gets PRIME regulatory status in Europe

Alkermes/Biogen hope for less tummy trouble with new MS pill

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biogen

Editor's Picks